Steven Cohen Obs Eva Sa Transaction History

Point72 Asset Management, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.01 - $5.05 $200,999 - $505,000	-100,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.89 - $2.55 $189,000 - $254,999	100,000 New	100,000 $208,000
Q3 2020 Nov 16, 2020	SELL	$2.46 - $6.15 $676,500 - $1.69 Million	-275,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.01 - $5.95 $447,626 - $1.33 Million	-222,700 Reduced 44.75%	275,000 $1.62 Million
Q1 2020 May 15, 2020	BUY	$1.87 - $4.47 $89,199 - $213,219	47,700 Added 10.6%	497,700 $1.2 Million
Q4 2019 Feb 14, 2020	BUY	$2.48 - $8.1 $552,447 - $1.8 Million	222,761 Added 98.03%	450,000 $1.72 Million
Q3 2019 Nov 15, 2019	SELL	$8.22 - $11.2 $159,969 - $217,963	-19,461 Reduced 7.89%	227,239 $1.89 Million
Q2 2019 Aug 14, 2019	SELL	$10.05 - $14.25 $234,165 - $332,025	-23,300 Reduced 8.63%	246,700 $2.79 Million
Q1 2019 May 15, 2019	BUY	$11.82 - $14.48 $827,400 - $1.01 Million	70,000 Added 35.0%	270,000 $3.45 Million
Q4 2018 Feb 14, 2019	BUY	$10.8 - $17.94 $270,000 - $448,500	25,000 Added 14.29%	200,000 $2.53 Million
Q3 2018 Nov 14, 2018	SELL	$10.92 - $18.18 $273,000 - $454,500	-25,000 Reduced 12.5%	175,000 $3.16 Million
Q2 2018 Aug 14, 2018	BUY	$10.0 - $17.87 $2 Million - $3.57 Million	200,000 New	200,000 $3.03 Million

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.